Farther Finance Advisors’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$682K Buy
2,311
+1,332
+136% +$351K ﹤0.01% 1359
2026
Q2
$222K Sell
979
-94
-9% -$16.7K ﹤0.01% 2171
2026
Q1
$188K Buy
1,073
+220
+26% +$40.8K ﹤0.01% 2063
2025
Q4
$170K Buy
853
+206
+32% +$37.4K ﹤0.01% 2017
2025
Q3
$101K Buy
647
+32
+5% +$5.08K ﹤0.01% 2039
2025
Q2
$93.3K Buy
615
+392
+176% +$52.3K ﹤0.01% 1791
2025
Q1
$32.6K Buy
223
+69
+45% +$11.6K ﹤0.01% 2122
2024
Q4
$28.4K Buy
154
+17
+12% +$3.27K ﹤0.01% 1925
2024
Q3
$27K Sell
137
-89
-39% -$18.5K ﹤0.01% 1953
2024
Q2
$45.9K Buy
226
+117
+107% +$26.5K ﹤0.01% 1455
2024
Q1
$29.3K Sell
109
-81
-43% -$19.3K ﹤0.01% 1374
2023
Q4
$44.9K Buy
190
+156
+459% +$30.7K ﹤0.01% 1072
2023
Q3
$6.66K Sell
34
-22
-39% -$4.52K ﹤0.01% 1418
2023
Q2
$11.8K Buy
56
+3
+6% +$597 ﹤0.01% 1143
2023
Q1
$10.7K Buy
53
+16
+43% +$3.63K ﹤0.01% 1090
2022
Q4
$8.06K Buy
+37
New +$8.08K ﹤0.01% 1015

Other funds holding CRL

Farther Finance Advisors's CRL Position: Q3 2026 in Review

Farther Finance Advisors increased its Charles River Laboratories (CRL) stake by 136% in Q3 2026, buying an estimated $351K and bringing the position to 2,311 shares worth $682K. The position accounts for ﹤0.01% of the portfolio, ranked #1359.

Farther Finance Advisors first reported a position in CRL in Q4 2022 and has held it in 16 quarters since. 15 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Farther Finance Advisors held 2,311 shares of Charles River Laboratories worth $682K as of Q3 2026.
  • Farther Finance Advisors bought 1,332 Charles River Laboratories shares in Q3 2026, an estimated $351K.
  • Charles River Laboratories made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #1359 holding.
  • Farther Finance Advisors first reported a position in Charles River Laboratories in Q4 2022 and has held it in 16 quarters since.
  • 15 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.